One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1910 articles with Amgen
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
First Biosimilar Avastin® and Herceptin® Products to Launch in the United States
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
Novartis, Amgen and Banner End Alzheimer's Program After Analysis Shows Patients' Conditions Wors...
7/12/2019The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program
Vendors in the cancer biologics market have significantly increased investments for the development of cancer treating biologic molecules.
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
Amgen Inc. ("Amgen") (NASDAQ:AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer") for SEK 32.50 per share in cash (the "Offer Price").(
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
The emergence of targeted therapies for the treatment of bone cancer is expected to drive market growth.
The award provides priority admission or a one-year renewal for lab bench space and access to core facilities at the MBC BioLabs life sciences incubator.
Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs.
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
Collaboration Will Apply IPD's de novo Protein Design Expertise to Biotech Drug Discovery
Amgen hopes the data will provide insights into specific diseases that will help develop new drugs.
The lawsuit was joined by Merck, Eli Lilly and Amgen. The companies claim the Department of Health and Human Services does not have the legal authority to force the companies to comply with the new rule.
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Amgen and Allergan plc announced that the U.S. Food and Drug Administration has approved KANJINTI™ for all approved indications of the reference product, Herceptin®: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
Shareholders in the United States should refer to the section entitled "Important Information to U.S. Shareholders" at the end of this press release.
Amgen will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in Rancho Palos Verdes, Calif.
University of Toronto and Amgen Foundation Welcome Canadian Students to Prestigious Amgen Scholars Program
For the first time, Amgen Foundation grant offers Canadian undergraduate students the opportunity to gain hands-on research experience with world-leading U of T researchers
Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®